Inhalation Sciences Sweden AbNGM: ISAB

ISAB: Sharp revenue drop and ongoing losses; financing and going concern remain key risks

· TradingView

Revenue declined sharply in 2025, with a significant operating loss and ongoing negative cash flow. The order backlog improved, but future financing remains uncertain, and a strategic review for potential sale is underway. Material uncertainty exists regarding going concern.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Inhalation Sciences Sweden Ab

All Inhalation Sciences Sweden Ab news releases